Many middle-income countries are missing critical, life-saving vaccines, which presents a threat to inter-country equity. Of the 19 countries that have transitioned from Gavi support, 13 have not yet introduced at least one of PCV, rotavirus, or HPV vaccines. And despite higher immunisation investments on average, a number of middle-income countries that have never been eligible for Gavi support are similarly lagging behind in introducing these vaccines relative to Gavi countries. Explore our resources that highlight good strategies and promising practices in new vaccine introduction.

Whilst most countries maintain programme performance following the transition from Gavi support, some have gaps in programmatic capacities which can create a risk of backsliding in vaccine coverage. This risk has increasingly become a reality in the context of the COVID-19 pandemic, presenting a significant threat to intra-country equity, as backsliding disproportionately impacts the most vulnerable populations. Explore our resources that highlight good strategies and promising practices to prevent and mitigate backsliding.

Gavi’s vision for a successful transition is one in which countries have expanded their national immunisation programmes with vaccines of public health importance and sustain these vaccines post-transition with high and equitable coverage of target populations, while having robust systems and decision-making processes in place to support the introduction of future vaccines. Explore our resources that highlight good strategies and promising practices for tackling challenges for transitioning countries.